EQ
Price:
$0.711
Market Cap:
$25.19M
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointesti...[Read more]
Industry
Biotechnology
IPO Date
2018-10-12
Stock Exchange
NASDAQ
Ticker
EQ
According to Equillium, Inc.’s latest financial reports and current stock price. The company's current ROE is -20.68%. This represents a change of 288.66% compared to the average of -5.32% of the last 4 quarters.
The mean historical ROE of Equillium, Inc. over the last ten years is -68.37%. The current -20.68% ROE has changed -69.76% with respect to the historical average. Over the past ten years (40 quarters), EQ's ROE was at its highest in in the September 2018 quarter at 47.37%. The ROE was at its lowest in in the March 2022 quarter at -114.89%.
Average
-68.37%
Median
-58.61%
Minimum
-337.20%
Maximum
100.43%
Discovering the peaks and valleys of Equillium, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 475.30%
Maximum Annual ROE = 100.43%
Minimum Annual Increase = -120.32%
Minimum Annual ROE = -337.20%
Year | ROE | Change |
---|---|---|
2023 | -59.08% | -82.48% |
2022 | -337.20% | 475.30% |
2021 | -58.61% | 37.54% |
2020 | -42.61% | -30.28% |
2019 | -61.12% | 199.53% |
2018 | -20.41% | -120.32% |
The current ROE of Equillium, Inc. (EQ) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-151.63%
5-year avg
-111.72%
10-year avg
-68.37%
Equillium, Inc.’s ROE is greater than Lyra Therapeutics, Inc. (-178.68%), greater than HOOKIPA Pharma Inc. (-49.25%), greater than LianBio (-21.53%), greater than Jasper Therapeutics, Inc. (-67.65%), greater than Cingulate Inc. (-113174.53%), greater than SAB Biotherapeutics, Inc. (-94.37%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Cadrenal Therapeutics, Inc. Common Stock (-142.95%), greater than Monopar Therapeutics Inc. (-21731.73%), less than Spero Therapeutics, Inc. (3.36%), greater than Bolt Biotherapeutics, Inc. (-69.46%), less than Coherus BioSciences, Inc. (0.40%), greater than Gracell Biotechnologies Inc. (-15.56%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than Ikena Oncology, Inc. (-39.59%), greater than Werewolf Therapeutics, Inc. (-58.83%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Quoin Pharmaceuticals, Ltd. (-126.19%), greater than Pasithea Therapeutics Corp. (-15595.10%), greater than aTyr Pharma, Inc. (-56.83%), greater than Trevi Therapeutics, Inc. (-63.30%), greater than Cue Biopharma, Inc. (-156.38%), greater than AN2 Therapeutics, Inc. (-57.63%), greater than BioAtla, Inc. (-187.30%),
Company | ROE | Market cap |
---|---|---|
-178.68% | $12.37M | |
-49.25% | $20.76M | |
-21.53% | $34.47M | |
-67.65% | $330.78M | |
-113174.53% | $15.42M | |
-94.37% | $28.89M | |
-184.40% | $37.86M | |
-142.95% | $24.86M | |
-21731.73% | $106.08M | |
3.36% | $63.24M | |
-69.46% | $22.14M | |
0.40% | $125.58M | |
-15.56% | $989.87M | |
-8.54% | $8.20M | |
-39.59% | $82.52M | |
-58.83% | $84.67M | |
-26.83% | $3.05B | |
-126.19% | $2.95M | |
-15595.10% | $3.93M | |
-56.83% | $131.12M | |
-63.30% | $223.68M | |
-156.38% | $64.62M | |
-57.63% | $39.99M | |
-187.30% | $75.90M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Equillium, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Equillium, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Equillium, Inc.'s ROE?
How is the ROE calculated for Equillium, Inc. (EQ)?
What is the highest ROE for Equillium, Inc. (EQ)?
What is the 3-year average ROE for Equillium, Inc. (EQ)?
What is the 5-year average ROE for Equillium, Inc. (EQ)?
How does the current ROE for Equillium, Inc. (EQ) compare to its historical average?